Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Opinion & analysis

Opinion & analysis


  • Sort by Popularity (sales)
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Immuno-Oncology: Unicorns, China And The Perfect Storm

    $200.00

    Immuo-oncology is proving to be that rare animal for investors in pharma, where return on invested capital doesn’t seem necessarily tied to risk, with mature assets returning liquidity similar to those of early assets.  Examine transaction trends, investor activity, and the exit landscape for this important area.

    October 24, 2018
    Find out more

  • Unilever Seeks End To Litigation Over St. Ives Scrub, Plaintiffs’ ‘Fake Medical Condition’

    $131.00

    “Junk science” is being blamed for a lawsuit filed against Unilever for alleged “micro-tears” caused by their St. Ives Apricot Scrub. The suit, first filed in 2016, may be coming to the end of the road, as Unilever requests a summary judgement in the matter.

    October 24, 2018
    Find out more

  • Nail Polishes Contain Undeclared DEHP, Among Other ‘Regrettable Substitutions’ – Study

    $200.00

    Plasticizer Dibutyl phthalate (DBP) is said to have been phased out of use in nail polishes, but a recent study by Harvard public health researchers wonders what is being used to replace the ingredient, and whether it is any safer than DBP.

    October 12, 2018
    Find out more

  • FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE

    $131.00

    NGO Women’s Voices for the Earth recently called for a ban of five ingredients used in fragrances for personal-care products. These ingredients were recently removed from the safe food additives list by the FDA, despite the FDA’s claims that they pose no risk to public health. Go deeper into this clash between hazard and risk ideologies in this informative article.

    October 18, 2018
    Find out more

  • What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It

    $131.00

    Find out more about the proposed The Safe Cosmetics and Personal Care Products Act 2018. This bill would institute a number of reforms for the industry and establish a new set of guidelines for safety, and is very similar to previous proposals for cosmetics reform submitted by Rep. Jan Schakowsky, D-Ill.

    September 29, 2018
    Find out more

  • DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

    $131.00

    “Almost everyone at Deciem has been involved in a major criminal activity.” So claimed Deciem Inc. founder Brandon Truaxe on an October 8 Instagram post in which he also announced the controversial Estee Lauder Companies-backed startup would be ceasing operations “until further notice.” Find out more here.

    October 9, 2018
    Find out more

  • Real-World Evidence: US FDA’s Prucalopride Review Shows Datasets’ Utility And Limitations

    $131.00

    Although criticism was leveled at the use of real-world datasets in the US FDA advisory committee review of Shire PLC’s constipation drug Motegrity (prucalopride) with worries raised over its lack of race-related patient information, a European pharmacoepidemiology study allayed concerns regarding its cardiovascular safety.

    October 23, 2018
    Find out more

  • Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says

    $131.00

    Explore the details behind the FDA digital health tools platform set for release in the fall of 2018, an initiative designed to allow health software applications and accompanying new drugs to be approved concurrently, further streamlining the approval process for certain combination products.

    October 24, 2018
    Find out more

  • Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

    $200.00

    Is a suffix that distinguishes biosimilars and other biologic products necessary in adverse event reporting? The US FDA says yes, although to date, nearly every adverse event report received by the FDA have identified biosimilars simply by their brand names.

    October 10, 2018
    Find out more

  • Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study

    $130.00

    On September 28, 2018, the US FDA issued new draft guidelines for adaptive clinical trial designs, as well as additional guidance updates. Tap into these important updates, which replace draft guidance issued by the agency in 2010.

    September 30, 2018
    Find out more

  • OTC Distribution in Europe – The New Global Agenda

    $2,845.00

    This comprehensive study identifies key factors driving change in the channels through which non-prescription/OTC medicines are distributed in Europe (18 main EU markets, plus Norway and Switzerland) and highlights the challenges facing suppliers in an ever-changing market.

    January 18, 2016
    Find out more

  • Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care

    $100.00

    Connected care technologies play an important role in disease prevention, but are still not used as widely as they should be. Philips’ second Future Health Index study surveyed 33,000 participants in 19 countries to compare perceptions and experiences of healthcare users across three areas – access to care, integration of health systems and adoption of connected care technologies.

    February 15, 2018
    Find out more

  • Game On For Akili’s Cognitive Control Tech

    $100.00

    A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD).

    February 5, 2018
    Find out more

  • Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps

    $100.00

    Victoria Hordern and Amy Merrick discuss initiatives in the EU to help app developers navigate the unclear rules on mobile health and explain why engaging patients during product development is key.

    February 5, 2018
    Find out more

  • Telehealth, Wearables and Apps – Report 3

    $300.00

    >  Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym
    >  Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s
    >  Interview: Philips Plugs Into Patient Connectivity

    December 1, 2017
    Find out more

  • Telehealth, Wearables and Apps – Report 2

    $400.00

    > Behind The Scenes Of Digital Health: Medtech Players And Partners
    >  Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care
    >  New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
    >  Siemens Healthineers To Launch Digital ‘One-Stop-Shop’

    December 1, 2017
    Find out more

  • Telehealth, Wearables and Apps – Report 1

    $400.00

    > Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps
    > Telehealth Reforms Praised At Senate Hearing
    > Philips’ Survey Highlights Gaps In Perceptions Of Health Care
    > Game On For Akili’s Cognitive Control Tech

    December 1, 2017
    Find out more

  • Special Report: The Intersection Between Tech and Pharma (Part 1. Google)

    $3,000.00

    In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow.

    January 2, 2016
    Find out more

  • Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 2

    $500.00

    OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

    March 16, 2017
    Find out more

  • Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 2

    $300.00

    Funding is taking a long time to come through for the UK NHS’s digital health care transformation, but as the national provider’s head of technology strategy, Dr Paul Rice says, “We can’t afford to remain non-digital.”

    July 21, 2017
    Find out more

  • Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 1

    $400.00

    The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes.

    March 31, 2017
    Find out more

  • Pharma Intelligence Report Store Article Collection Digital Patient Management

    $200.00

    The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.

    April 25, 2017
    Find out more

  • Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 1

    $500.00

    Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.

    November 22, 2016
    Find out more

  • Pharma Intelligence Report Store Article: Collection Cybersecurity

    $300.00

    Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.

    May 19, 2017
    Find out more
  • Transforming Pharmaceutical R&D with Data

    Transforming Pharmaceutical R&D with Data

    $2,995.00

    Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable.  The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%

    May 2, 2017
    Find out more

  • Data in Healthcare: Underpinning the Shift to Value

    $2,995.00

    Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.

    November 23, 2016
    Find out more

  • Wearables are Transforming R&D and Care Delivery

    $2,995.00

    Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.

    June 6, 2016
    Find out more

  • The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

    $3,000.00

    The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

    January 22, 2016
    Find out more

  • The Intersection Between Tech and Pharma Special Report (Part 2. Apple)

    $3,000.00

    In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

    January 14, 2016
    Find out more
Page 10 of 10
Page 10 of 10«‹8910
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top